Analisi di costo della terapia con celecoxib vs FANS tradizionali nell’artrosi in Italia


Cost-analysis of a 6-week cycle of therapy with celecoxib vs conventional NSAIDs in ostheoarthritis in Italy



To estimate the cost in the Italian National Health Service (INHS) perspective of a 6-week treatment course with celecoxib vs NSAIDs in ostheoarthritis patients.


A decision-tree analysis with a 6-week time-frame.

Main outcome measures and results

Costs included the acquisition cost of celecoxib 200 mg/day and of a basket of the first ten prescribed NSAIDs in Italy during the year 2000. Probabilities of side effects were derived from clinical trials comparing celecoxib vs NSAIDs and adjusted for 6-week exposure. Costs to treat the adverse events and probability of hospitalization were derived from a previous study conducted in Italy among GPs. Sensitivity and treshold analyses were conducted to test the robustness of the model. In the 6-week period, celecoxib resulted the less expensive strategy vs NSAIDs (€ 72,35 vs 78,63). Probability of serious events with NSAIDs was most critical for the results and the cost-effectiveness of the new therapy was correlated to the risk of serious events with NSAIDs.


According to our study results, celecoxib represents a cost-effective first-line strategy alternative to NSAIDs for the symptomatic therapy of ostheoarthritis in Italy.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Ciocci A. Le malattie reumatiche: aspetto statistico della malattia. Bollettino di Informazioni Medico-Statistiche 1984; 4: 14–21Google Scholar
  2. 2.
    Borda IT. The spectrum of adverse gastrointestinal effects associated with nonsteroidal anti-inflammatory drugs. In: Borda IT, Koff RS, eds. NSAIDs: a profile of adverse effects. Philadelphia: Mosby-Year Book, 1992: pp 25–80Google Scholar
  3. 3.
    Gabriel SE, Jaakkimainen L, Bombardier C. Risk of serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Inter Med 1991; 115:787–96Google Scholar
  4. 4.
    Fries JF, Miller SR, Spitz PW, et al. Toward an epidemiology of gastropathy associated with nonsteroidal antinflammatory drug use. Gastroenterology 1989; 96: 647–55PubMedGoogle Scholar
  5. 5.
    Tramer MR, Moore RA, Reynolds DJ, McQuay HJ. Quantitative estimation of rare adverse events which follow a biological progression: a new model applied to chronic NSAIDs use. Pain 2000; 85: 169–82PubMedCrossRefGoogle Scholar
  6. 6.
    Griffin MR. Epidemiology of nonsteroidal anti-inflammatory drug-associated gastrointestinal injury. Am J Med 1998; 105: 3S–9SCrossRefGoogle Scholar
  7. 7.
    Hawkey CJ. Nonsteroidal anti-inflammatory drug gastropathy. Gastroenterology 2000; 119: 521–35PubMedCrossRefGoogle Scholar
  8. 8.
    Langman MJ. Epidemiology of non-steroidal anti-inflammatory drug damage to stomach and duodenum. Ital J Gastroenterol Hepatol 1999; 31: S2–S5PubMedGoogle Scholar
  9. 9.
    Hernandez-Diaz S, Garcia Rodriguez L. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation. Arch Intern Med 2000; 160: 2093–9PubMedCrossRefGoogle Scholar
  10. 10.
    Nobili A, Mosconi P, Franzosi MG, Tognoni G. Nonsteroidal anti-inflammatory drugs and upper gastrointestinal bleeding, a post-marketing surveillance case-control study. Pharmacoepidemiol Drug Safety 1992; 1: 65–72CrossRefGoogle Scholar
  11. 11.
    Savage RL, Moller PV, Ballantyne CL, Wells JE. Variation in the risk of peptic ulcer complications with nonsteroidal antinflammatory drug therapy. Arthritis Rheum 1993; 36: 84–90PubMedCrossRefGoogle Scholar
  12. 12.
    Lanza LL, Walker AM, Boetnichack EA, Dreyer NA. Peptic ulcer and gastrointestinal hemorrage associated with nonsteroidal anti-inflammatory drug use in patients younger than 65 years: a large health maintenance organization cohort study. Arch Intern Med 1995; 155: 1371–7PubMedCrossRefGoogle Scholar
  13. 13.
    Hallas J, Lauritsen J, Dalsgard Villadsen H, Gram LF. Nonsteroidal anti-inflammatory drugs and upper gastrointestinal bleeding, identifying high-risk group by excess risk estimates. Scand J Gastroenterol 1995; 30: 438–44PubMedCrossRefGoogle Scholar
  14. 14.
    Perez-Gutthann S, Garcia-Rodriguez LA, Raiford DS. Individual nonsteroidal antiinflammatory drugs and other risk factors for upper gastrointestinal bleeding and perforation. Epidemiology 1997; 8: 18–24CrossRefGoogle Scholar
  15. 15.
    Bidaut-Russell M, Gabriel SE. Adverse gastrointestinal effects of NSAIDs: consequences and costs. Best Pract Res Clin Gastroenterol 2001; 15(5): 739–53PubMedCrossRefGoogle Scholar
  16. 16.
    Mc Donald TM, Morant SV, Robinson GC, et al, Association of upper gastrointestinal toxicity of non-steroidal anti-inflammatory drugs with continued exposure: cohort study. BMJ 1997; 315: 1333–7CrossRefGoogle Scholar
  17. 17.
    Aalykke C, Lauritsen K. Epidemiology of NSAIDs-related gastroduodenal mucosal injury. Best Pract Res Clin Gastroenterol 2001; 15: 705–22PubMedCrossRefGoogle Scholar
  18. 18.
    Singh G. Recent considerations in nonsteroidal anti-inflammatory drug gastropathy. Am J Med 1998; 105(1B): 31S–8SPubMedCrossRefGoogle Scholar
  19. 19.
    Langman MJ, Weil J, Wainwright P, et al. Risk of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994; 343: 1075–8PubMedCrossRefGoogle Scholar
  20. 20.
    Griffin MR, Piper JM, Daugherty JR, et al. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann Intern Med. 1991; 114: 257–63PubMedGoogle Scholar
  21. 21.
    Henry D, Dobson A, Turner C. Variability in the risk of major gastrointestinal complications from non-aspirin nonsteroidal anti-inflammatory drugs. Gastroenterology 1993; 105: 1078–88PubMedGoogle Scholar
  22. 22.
    Beard K, Walker AM, Perera DR, Jick H. Nonsteroidal anti-inflammatory drugs and hospitalization for gastroesophageal bleeding in the elderly. Arch Int Med 1987; 147: 1621–3CrossRefGoogle Scholar
  23. 23.
    Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995; 123(4): 241–9PubMedGoogle Scholar
  24. 24.
    Sheen CL, MacDonald TM. Gastrointestinal side effects of NSAIDs — pharmacoeconomic implications. Expert Opin Pharmacother 2002; 3(3): 265–9PubMedCrossRefGoogle Scholar
  25. 25.
    Moore N, Verschuren X, Montout C, et al. Excess costs related to non-steroidal anti-inflammatory drug utilization in general practice.Therapie 2000; 55(1): 133–6PubMedGoogle Scholar
  26. 26.
    Rahme E, Joseph L, Kong SX, et al. Gastrointestinal health care resource use and costs associated with nonsteroidal antiinflammatory drugs versus acetaminophen: retrospective cohort study of an elderly population. Arthritis Rheum 2000; 43(4): 917–24PubMedCrossRefGoogle Scholar
  27. 27.
    de Pouvourville G. The economic consequences of NSAID-induced gastropathy: the French context. Scand J Rheumatol 1992; 96 (suppl): 49–53CrossRefGoogle Scholar
  28. 28.
    Knill-Jones RP. The economic consequences of NSAID-induced gastropathy in the United Kingdom and commentary on the article by G. de Pouvourville. Scand J Rheumatol 1992; 96 (suppl): 59–62CrossRefGoogle Scholar
  29. 29.
    Jonsson B, Haglund U. Economic burden of NSAID-induced gastropathy in Sweden. Scand J Gastroenterol 2001; 36(7): 775–9PubMedCrossRefGoogle Scholar
  30. 30.
    Herings RM, Klungel OH. An epidemiological approach to assess the economic burden of NSAID-induced gastrointestinal events in The Netherlands. Pharmacoeconomics 2001; 19(6): 655–65PubMedCrossRefGoogle Scholar
  31. 31.
    Sturkenboom MC, Romano F, Simon G, et al. The iatrogenic costs of NSAID therapy: A population study. Arthritis Rheum 2002; 47(2): 132–40PubMedCrossRefGoogle Scholar
  32. 32.
    Scarpato S, Acampora R, Corsaro S, et al. La gastroprotezione da farmaci antinfiammatori non steroidei e steroidi nelle divisioni di medicina interna: indagine sugli orientamenti prescrittivi dei medici internisti ospedalieri (Progetto Gardenia). Ann Ital Med Int 2002; 17: 41–6PubMedGoogle Scholar
  33. 33.
    Chevat C, Pena BM, Al MJ, Rutten FF. Healthcare resource utilization and cost of treating NSAID-associated gastrointestinal toxicity. Pharmacoeconomics 2001; 19 (Suppl 1): 17–32PubMedCrossRefGoogle Scholar
  34. 34.
    Blower AL, Brooks A, Fenn GC, et al. Emergency admission for upper gastrointestinal disease and their relation to NSAID use. Aliment Pharmacol Ther 1997; 11(2): 283–91PubMedCrossRefGoogle Scholar
  35. 35.
    Wolfe F, Kleinheksel SM, Spitz PW, et al. A multicenter study of hospitalization in rheumatoid arthritis. Frequency, medical-surgical admissions, and charges. Arthritis Rheum 1986; 29: 614–9PubMedCrossRefGoogle Scholar
  36. 36.
    Kolodny AL, Klipper A. Final report on the cost of treating arthritic disease: comparison between salicylates and nonsalicylate nonsteroidal anti-inflammatory drugs. Seminar in Arthritis & Rheumatism 1985; 14 (Suppl 1): 20–4CrossRefGoogle Scholar
  37. 37.
    Bloom BS. Cost of treating arthritis and NSAIDs related gastrointestinal side effects. Aliment Pharmacol Ther 1988; 2 (Suppl 1): 131–8PubMedGoogle Scholar
  38. 38.
    Walan A, Wahlquist P. Pharmacoeconomic aspects of non-steroidal anti-inflammatory drug gastropathy. Ital J Gastroenterol Hepatol 1993; 31 (Suppl 1): S79–S88Google Scholar
  39. 39.
    McDonald TM. Epidemiology and pharmacoeconomic implications of non-steroidal anti-inflammatory drug-associated gastrointestinal toxicity. Rheumatology 2000; 39 (Suppl 2): 13–20CrossRefGoogle Scholar
  40. 40.
    Zhao SZ, Arguelles LM, Dedhiya SD, Morgan DG. Healthcare utilization associated with dyspepsia in patients with arthritis. Am J Manag Care 1999; 5(10): 1285–95PubMedGoogle Scholar
  41. 41.
    Malfertheiner P, Stanghellini V, Galmiche JP, Jones RH. Review article: managing the dyspeptic patient-an interactive discussion Aliment Pharmacol Ther 2001;15 (Suppl 2): 14–9CrossRefGoogle Scholar
  42. 42.
    Delaney BC, Innes MA, Deeks J, et al. Initial management strategies for dyspepsia. Cochrane Database Syst Rev 2001; (3): CD001961Google Scholar
  43. 43.
    Pillans PI, Kubler PA, Radford JM, Overland V. Concordance between use of proton pump inhibitors and prescribing guidelines. Med J Aust 2000; 172(1): 16–8PubMedGoogle Scholar
  44. 44.
    Hungin AP, Rubin GP, O’Flanagan H. Long-term prescribing of proton pump inhibitors in general practice. Br J Gen Pract 1999; 49(443): 451–3PubMedGoogle Scholar
  45. 45.
    Chiroli S, Roggeri D. Consumo di risorse e costi per la diagnosi e la cura degli eventi avversi gastrointestinali dovuti all’uso dei FANS. Pharmacoeconomics-Italian Research Articles 2001; 2: 61–70Google Scholar
  46. 46.
    Leardini G, Mascia MT, Stisi S, et al. Il consumo di risorse sanitarie per la cura dell’artrosi. Reumatismo 2001; 53(3): 316–22PubMedGoogle Scholar
  47. 47.
    Clemett D, Goa KL. Celecoxib: a review of its use in osteoarthritis, rheumatoid arthritis and acute pain. Drugs 2000; 59(4): 957–80PubMedCrossRefGoogle Scholar
  48. 48.
    McKenna F, Borenstein D, Wendt H, et al. Celecoxib versus diclofenac in the management of osteoarthritis of the knee. Scand J Rheumatol 2001; 30(1): 11–8PubMedCrossRefGoogle Scholar
  49. 49.
    Goldenberg MM. Celecoxib, a selective cyclooxygenase-2 inhibitor for the treatment of rheumatoid arthritis and osteoarthritis. Clin Ther 1999; 21(9): 1497–513; discussion 1427-8PubMedCrossRefGoogle Scholar
  50. 50.
    Bensen WG, Fiechtner JJ, McMillen JI, et al. Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial. Mayo Clin Proc 1999; 74(11): 1095–105PubMedCrossRefGoogle Scholar
  51. 51.
    Kivitz AJ, Moskowitz RW, Woods E, et al. Comparative efficacy and safety of celecoxib and naproxen in the treatment of osteoarthritis of the hip. J Int Med Res 2001; 29(6): 467–79PubMedGoogle Scholar
  52. 52.
    Tive L. Celecoxib clinical profile. Rheumatology (Oxford) 2000; 39 (Suppl 2): 21–8; discussion 57-9CrossRefGoogle Scholar
  53. 53.
    Zhao SZ, McMillen JI, Markenson JA, et al. Evaluation of the functional status aspects of health-related quality of life of patients with osteoarthritis treated with celecoxib. Pharmacotherapy 1999; 19(11): 1269–78PubMedCrossRefGoogle Scholar
  54. 54.
    Lisse J, Espinoza L, Zhao SZ, et al. Functional status and health-related quality of life of elderly osteoarthritic patients treated with celecoxib. J Gerontol A Biol Sci Med Sci 2001; 56(3): M167–75PubMedCrossRefGoogle Scholar
  55. 55.
    Bensen WG. Antiinflammatory and analgesic efficacy of COX-2 specific inhibition: from investigational trials to clinical experience. J Rheumatol Suppl 2000; 60: 17–24.PubMedGoogle Scholar
  56. 56.
    Bensen WG, Zhao SZ, Burke TA, et al. Upper gastrointestinal tolerability of celecoxib, a COX-2 specific inhibitor, compared to naproxen and placebo. J Rheumatol 2000; 27: 1876–83PubMedGoogle Scholar
  57. 57.
    McKenna F, Arguelles L, Burke T, et al. Upper gastrointestinal tolerability of celecoxib compared with diclofenac in the treatment of osteoarthritis and rheumatoid arthritis. Clin Exp Rheumatol 2002; 20: 35–43PubMedGoogle Scholar
  58. 58.
    Goldstein JL, Correa P, Zhao WW, et al. Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis. Am J Gastroenterol 2001; 96(4): 1019–27PubMedCrossRefGoogle Scholar
  59. 59.
    Emery P, Zeidler H, Kvien TK, et al. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. Lancet 1999; 354(9196): 2106–11PubMedCrossRefGoogle Scholar
  60. 60.
    Simon LS, Weaver AL, Graham DY, et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA 1999; 282(20): 1921–8PubMedCrossRefGoogle Scholar
  61. 61.
    Simon LS, Lanza FL, Lipsky PE, et al. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects. Arthritis Rheum 1998; 41(9): 1591–602PubMedCrossRefGoogle Scholar
  62. 62.
    Ashcroft DM, Chapman SR, Clark WK, Millson DS. Upper gastroduodenal ulceration in arthritis patients treated with celecoxib. Ann Pharmacother 2001; 35(7–8): 829–34PubMedCrossRefGoogle Scholar
  63. 63.
    Burke TA, Zabinski RA, Pettitt D, et al. A framework for evaluating the clinical consequences of initial therapy with NSAIDs, NSAIDs plus gastroprotective agents or celecoxib in the treatment of arthritis. Pharmacoeconomics 2001; 19 (Suppl 1): 33–47PubMedCrossRefGoogle Scholar
  64. 64.
    Wolfe F, Anderson J, Burke TA, et al. Gastroprotective therapy and risk of gastrointestinal ulcers: risk reduction by COX-2 therapy. J Rheumatol 2002; 29(3): 467–73PubMedGoogle Scholar
  65. 65.
    Goldstein JL. Significant upper gastrointestinal events associated with conventional NSAID versus celecoxib. J Rheumatol Suppl. 2000; 60: 25–8PubMedGoogle Scholar
  66. 66.
    Goldstein JL, Silverstein FE, Agrawal NM, et al. Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor. Am J Gastroenterol 2000; 95(7): 1681–90PubMedCrossRefGoogle Scholar
  67. 67.
    Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib long-term arthritis safety study. JAMA 2000; 284(10): 1247–55PubMedCrossRefGoogle Scholar
  68. 68.
    Goldstein JL. Significant reduction in serious upper gastrointestinal (UGI) events with celecoxib, a COX-2 specific inhibitor, compared with conventional NSAIDs. The SUCCESS I Trial. Gastroenterology 2001; 120 (Suppl 1):A105Google Scholar
  69. 69.
    Simon LS, Zhao SZ, Arguelles LM, et al. Economic and gastrointestinal safety comparison of etodolac, nabumetone and oxaprozin from insurance claims data from patients with arthritis. Clin Ther 1998; 20: 1218–35PubMedCrossRefGoogle Scholar
  70. 70.
    Hogan DB, Campbell NR, Critcher R, et al. Prescription of nonsteroidal anti-inflammatory drugs for elderly people in Alberta. Can Med Assoc J 1994; 151: 315–22Google Scholar
  71. 71.
    Caruso I, Bianchi Porro G. Gastroscopic evaluation of antinflammatory agents. BMJ 1980; 280: 75–78PubMedCrossRefGoogle Scholar
  72. 72.
    Garcia Rodriguez LA, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal antiinflammatory drugs. Lancet 1994; 343: 769–72PubMedCrossRefGoogle Scholar
  73. 73.
    Lanza FL, Royer GL, Nelson RS, et al. A comparative endoscopic evaluation of damaging effects of nonsteroidal antiinflammatory agents on the gastric and duodenal mucosa. Am J Gastroenterol 1981; 75: 17–21PubMedGoogle Scholar
  74. 74.
    Carson JL, Strom BL, Morse ML, et al. The relative gastrointestinal toxicity of the nonsteroidal antiinflammatory drugs. Arch Intern Med 1987; 147: 1054–9PubMedCrossRefGoogle Scholar
  75. 75.
    Fries JF, Spitz PW, Williams CA, et al. A toxicity index for comparison of side effects among different drugs. Arthritis Rheum 1990; 33: 121–30PubMedCrossRefGoogle Scholar
  76. 76.
    Singh G, Ramley DR, Morfeld D, Fries JF. Comparative toxicity of non-steroidal antiinflammatory agents. Pharmacol Ther 1994; 62: 1750–91CrossRefGoogle Scholar
  77. 77.
    Pettitt D, Goldstein JL, McGuire A, et al. Overview of the arthritis Cost Consequence Evaluation System (ACCES): a pharmacoeconomic model for celecoxib. Rheumatology (Oxford). 2000; 39 (Suppl 2): 33–42; discussion 57-9CrossRefGoogle Scholar
  78. 78.
    Chancellor JV, Hunsche E, de Cruz E, Sarasin FP. Economic evaluation of celecoxib, a new cyclo-oxygenase 2 specific inhibitor, in Switzerland. Pharmacoeconomics 2001; 19 (Suppl 1): 59–75PubMedCrossRefGoogle Scholar
  79. 79.
    Zabinski RA, Burke TA, Johnson J, et al. An economic model for determining the costs and consequences of using various treatment alternatives for the management of arthritis in Canada. Pharmacoeconomics 2001; 19 (Suppl 1): 49–58PubMedCrossRefGoogle Scholar
  80. 80.
    Haglund U, Svarvar P. The Swedish ACCES model: predicting the health economic impact of celecoxib in patients with osteoarthritis or rheumatoid arthritis. Rheumatology (Oxford) 2000; 39 (Suppl 2): 51–6CrossRefGoogle Scholar
  81. 81.
    Svarvar P, Aly A. Use of the ACCES model to predict the health economic impact of celecoxib in patients with osteoarthritis or rheumatoid arthritis in Norway. Rheumatology (Oxford) 2000; 3439 (Suppl 2): 43–50CrossRefGoogle Scholar
  82. 82.
    Hrachovec JB, Mora M. Reporting of 6-months vs 12-months data in a clinical trial of celecoxib. JAMA 2001; 286: 2398PubMedCrossRefGoogle Scholar
  83. 83.
    Silverstein F, Simon L, Faich G. Reply to “Reporting of 6-months vs 12-months data in a clinical trial of celecoxib”. JAMA 2001; 286: 2399Google Scholar
  84. 84.
    Jüni P, Rutjes AWS, Dieppe PA. Are selective COX-2 inhibitors superior to traditional non-steroidal antiinflammatory drugs? BMJ 2002; 324: 1287–8PubMedCrossRefGoogle Scholar
  85. 85.
    Geis GS. Reply to “Are selective COX-2 inhibitors superior to traditional non-steroidal antiinflammatory drugs?”. BMJ 2002; 325: 161–2PubMedCrossRefGoogle Scholar
  86. 86.
    Goldstein JL for the CLASS investigators. Gastrointestinal (GI) event rates in the CLASS study: six-months vs longer term follow-up analysis. Gastroenterology 2002; 122 (Suppl 1): A469Google Scholar
  87. 87.
    Deeks JJ, Smith LA, Bradley MD. Efficacy, tolerability and upper gastrointestinal safety of celecoxib for the treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials. BMJ 2002; 325: 619–27PubMedCrossRefGoogle Scholar
  88. 88.
    Lu HL. Statistical reviewer briefing document for the advisory committee. (accessibile al 3 giugno 2002)

Copyright information

© Adis International Limited 2003

Authors and Affiliations

  • Carlo Lucioni
    • 1
  • S. Chiroli
    • 2
  • D. Roggeri
    • 2
  • G. Annoni
    • 3
  1. 1.ADIS International/Health EconomicsMilanoItalia
  2. 2.Outcome ResearchPharmacia Italia SpAMilanoItalia
  3. 3.DIMEPUniversità degli Studi di Milano-BicoccaMonza (MI)Italia

Personalised recommendations